RBC Capital resumed coverage of Bio-Rad (BIO) with an Outperform rating and $320 price target The company’s sales growth should recover in 2027 following “idiosyncratic product headwinds” in 2026, the analyst tells investors in a research note. RBC expects Bio-Rad’s new management to structurally improve the company’s margin profile.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: